Andersen KM, Kelly A, Lyddiatt A, et al. - Core safety domains that matter most to patients with rheumatic disease were investigated by the Outcome Measures in Rheumatology (OMERACT) Safety Working Group. Thirty-nine patients with inflammatory arthritis were held in international focus groups to determine their disease-modifying antirheumatic drug (DMARD) experiences and concerns. As per observations, overall adverse effects and benefits over time are weighed in relation to experiences and life circumstances by the patients.